Propanc Biopharma (PPCB) Income from Continuing Operations (2010 - 2025)
Propanc Biopharma (PPCB) posted quarterly Income from Continuing Operations of 3091394.0 for Q4 2025, down 618.62% year-over-year from 596077.3 in Q4 2024, and up 36.1% quarter-over-quarter from 4837738.0 in Q3 2025.
Propanc Biopharma (PPCB) Income from Continuing Operations (2010 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Income from Continuing Operations for 16 consecutive years, with 3091394.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 618.62% year-over-year to 3091394.0; the TTM figure through Dec 2025 stood at 66067939.0 (down 3856.71% YoY), while the FY2025 annual figure was 58923300.0, down 3136.6% from the prior year.
- Income from Continuing Operations grew to 3091394.0 in Q4 2025 per PPCB's latest filing, from 4837738.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 350866.0 in Q3 2023 and bottomed at 54067346.0 in Q1 2025.
- Historically, Income from Continuing Operations has averaged 3759418.6 across 5 years, with a median of 600839.5 in 2022.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations soared 83.84% — and 2025, when it sank 10165.3%.
- Propanc Biopharma's Income from Continuing Operations stood at 799977.0 in 2021, then jumped by 39.32% to 485418.0 in 2022, then decreased by 20.39% to 584384.0 in 2023, then gained by 26.39% to 430183.0 in 2024, then plunged by 618.62% to 3091394.0 in 2025.
- Business Quant data shows PPCB's Income from Continuing Operations at 3091394.0 in Q4 2025, 4837738.0 in Q3 2025, and 4071461.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | -3.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.09 Mn |
| Sep 30, 2025 | -4.84 Mn |
| Jun 30, 2025 | -4.07 Mn |
| Mar 31, 2025 | -54.07 Mn |
| Dec 31, 2024 | -430,183.00 |
| Sep 30, 2024 | -354,310.00 |
| Jun 30, 2024 | -358,578.00 |
| Mar 31, 2024 | -526,700.00 |
| Dec 31, 2023 | -584,384.00 |
| Sep 30, 2023 | -350,866.00 |
| Jun 30, 2023 | -748,044.00 |
| Mar 31, 2023 | -809,809.00 |
| Dec 31, 2022 | -485,418.00 |
| Sep 30, 2022 | -617,295.00 |
| Jun 30, 2022 | -904,765.00 |
| Mar 31, 2022 | -462,687.00 |
| Dec 31, 2021 | -799,977.00 |
| Sep 30, 2021 | -490,658.00 |
| Jun 30, 2021 | -779,021.00 |
| Mar 31, 2021 | -417,738.00 |